Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
Subscribe To Our Newsletter & Stay Updated
